Gene · 8913
CACNA1G: calcium voltage-gated channel subunit alpha1 G
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. CACNA1G: calcium voltage-gated channel subunit alpha1 G. Genes, record 8913. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/8913
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| O43497 | Voltage-dependent T-type calcium channel subunit alpha-1G | 2,377 | 2 | Ensembl, GeneID, HGNC |
Source UniProt
Patents25
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4641201 A2 | 2025-10-29 | 7657 | O43497 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 693 | O43497 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 693 | O43497 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 7657 | O43497 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 10787 | O43497 | Espacenet |
| JP 2025032204 A | 2025-03-11 | 25537 | O43497 | Espacenet |
| EP 4461818 A2 | 2024-11-13 | 25537 | O43497 | Espacenet |
| JP 2023058610 A | 2023-04-25 | 25537 | O43497 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 10787 | O43497 | Espacenet |
| US 11400116 B2 | 2022-08-02 | 4496 | O43497 | Espacenet |
1 to 10 of 25
See all 25 patentsDrugs20
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| APINOCALTAMIDE | CHEMBL4217292 | Voltage-gated T-type calcium channel blocker | BLOCKER | ChEMBL |
| ATAGABALIN | CHEMBL593430 | Voltage-gated calcium channel modulator | MODULATOR | ChEMBL |
| BEPRIDIL | CHEMBL1008 | Voltage-gated calcium channel blocker | BLOCKER | ChEMBL |
| BEPRIDIL HYDROCHLORIDE | CHEMBL1200382 | Voltage-gated calcium channel blocker | BLOCKER | ChEMBL |
| ETHOSUXIMIDE | CHEMBL696 | Voltage-gated T-type calcium channel blocker | BLOCKER | ChEMBL |
| GABAPENTIN | CHEMBL940 | Voltage-gated calcium channel modulator | MODULATOR | ChEMBL |
| GABAPENTIN ENACARBIL | CHEMBL1628502 | Voltage-gated calcium channel modulator | MODULATOR | ChEMBL |
| IMAGABALIN | CHEMBL2103836 | Voltage-gated calcium channel modulator | MODULATOR | ChEMBL |
| METHSUXIMIDE | CHEMBL697 | Voltage-gated T-type calcium channel blocker | BLOCKER | ChEMBL |
| MIBEFRADIL | CHEMBL45816 | Voltage-gated T-type calcium channel blocker | BLOCKER | ChEMBL |
1 to 10 of 20
See all 20 drugsTrials386
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07606638 | PREGABALIN | ClinicalTrials.gov | ||
| NCT07598474 | PREGABALIN | ClinicalTrials.gov | ||
| NCT07429734 | GABAPENTIN | PHASE3 | ClinicalTrials.gov | |
| NCT07382921 | PREGABALIN | ClinicalTrials.gov | ||
| NCT07344467 | PREGABALIN | ClinicalTrials.gov | ||
| NCT07230197 | PREGABALIN | ClinicalTrials.gov | ||
| NCT07230171 | PREGABALIN | ClinicalTrials.gov | ||
| NCT07208357 | PREGABALIN | ClinicalTrials.gov | ||
| NCT07196657 | PREGABALIN | ClinicalTrials.gov | ||
| NCT07186751 | PREGABALIN | ClinicalTrials.gov |
1 to 10 of 386
See all 386 trialsNIH grants1,078
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | CACNA1G papers | Newest fiscal year |
|---|---|---|---|
| U01CA167552 | Cancer Epidemiology Cohort in Male Health Professionals | 15 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 10 | 2025 |
| P30DK043351 | Center for the Study of Inflammatory Bowel Disease at Massachusetts General Hospital | 9 | 2025 |
| R01CA248857 | Interdisciplinary Epidemiologic Consortium to Investigate T-cell Response in Colorectal Cancer | 7 | 2025 |
| P30CA015704 | Cancer Center Support Grant | 6 | 2025 |
| R35GM141802 | Voltage-gated calcium channels as target for anesthetics | 5 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 4 | 2025 |
| P30CA012197 | Cancer Center Support Grant | 4 | 2025 |
| R01HL135109 | Targeting the Arrhythmogenic Sources of Human Atrial Fibrillation | 4 | 2025 |
| R35CA253185 | Precision Prevention Research Program | 4 | 2025 |
1 to 10 of 1,078Source NIH's project files
See all 1,078 nih grantsPapers1,769
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Diterpenoid alkaloids from Delphinium aemulans Nevski and their analgesic and ion channel inhibitory activities. | Phytochemistry | 2027 | 42710726 | PubTator, text mining | PubMed |
| Ginsenoside Rg2 inhibits the cell viability of cisplatin-resistant epithelial ovarian cancer by suppressing CACNA1G-mediated calcium signaling. | Toxicol Appl Pharmacol | 2026 | 42727823 | PubTator, text mining | PubMed |
| Ion-Channel Activity of Characteristic Alkaloids From Uncaria rhynchophylla. | Chem Biodivers | 2026 | 42720106 | PubTator, text mining | PubMed |
| The expanding role of Cav3 channels in glioblastoma. | Trends Pharmacol Sci | 2026 | 42697770 | PubTator, text mining | PubMed |
| Comparative transcriptomics analysis of histone deacetylases, transcription factors, and ion channel genes in human iPSC-cardiomyocytes vs. the adult human heart. | J Precis Med (Amst) | 2026 | 42644057 | PubTator, text mining | PubMed |
| A novel de novo CACNA1G variant p.(Arg1553Gln) associated with neurodevelopmental delay and cerebellar hypoplasia: Expanding the phenotypic spectrum. | Eur J Med Genet | 2026 | 42309484 | PubTator, text mining | PubMed |
| Molecular Pharmacology of T-Type Calcium Channels and Their Roles in Neurological Disorders. | Med Res Rev | 2026 | 42272247 | PubTator, text mining | PubMed |
| Endurance exercise remodels pulmonary vein sleeve myocytes and promotes a proarrhythmic atrial substrate. | Eur Heart J | 2026 | 42178147 | PubTator, text mining | PubMed |
| The four voltage-sensing domains of T-type calcium channels activate near the resting membrane potential. | Nat Commun | 2026 | 42143043 | PubTator, text mining | PubMed |
| Novel Truncating Variant c.1222DupC in RBM20 Causes Cardiomyopathy Consistent With Haploinsufficiency. | Circ Genom Precis Med | 2026 | 42059065 | PubTator, text mining | PubMed |
1 to 10 of 1,769
See all 1,769 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/8913
GET https://conductscience.org/api/genes/v1/8913/patents?page=2